NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Drug Manufacturers - Specialty & Generic · USD

Aytu BioPharma, Inc. (AYTU) Stock Analysis

Aytu BioPharma, Inc. (AYTU) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

AYTU

$2.21

−$0.08 (−3.49%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare AYTU with… →

AYTU Key Statistics

As of Sep 4, 2026
Trading
Open
$2.24
Previous Close
$2.29
Day's Range
2.19–2.39
52-Week Range
1.65–3.07
Volume
15.90K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.27
Valuation
Market Cap
$23.72M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
0.42
EPS (ttm)Profit attributable to each share over the last twelve months.
−4.38
Financials (FY)
Revenue (FY)
$66.38M+1.84%
Net Income (FY)
−$13.56M
Profit marginThe share of revenue left as profit after all costs and taxes.
−60.17%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
10.73M
1-Year Return
−2.21%
Dividend and dates
Avg Volume
26.10K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

AYTU Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−15.00%
2025+52.94%
2024−40.14%
2023−25.26%
2022−85.93%
2021−77.42%
2020−38.35%
2019+22.78%
2018−98.23%
2017−90.71%
2016 (partial year)−66.67%

As of September 4, 2026.

AYTU Revenue and Earnings by Fiscal Year

FY ends June
Fiscal yearRevenueNet incomeNet margin
2025$66.38M−$13.56M−20.4%
2024$65.18M−$15.84M−24.3%
2023$107.40M−$17.05M−15.9%
2022$96.67M−$108.78M−112.5%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$66.38M$45.83M$2.54M−$13.56M−20.4%
2024$65.18M$49.05M$565.00K−$15.84M−24.3%
2023$107.40M$66.63M−$12.33M−$17.05M−15.9%
2022$96.67M$52.28M−$36.10M−$108.78M−112.5%

Annual figures as reported, in the company's reporting currency. As of June 30, 2025.

AYTU Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 103 stocks
MetricAYTUDrug Manufacturers - Specialty & Generic medianvs median
P/S ratio0.422.300.2x the median
Profit margin−60.17%−3.14%57.0 pts below

Medians across 103 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Aytu BioPharma, Inc. (AYTU) is capitalised at $23.72M on the latest close. The company sits in the Healthcare sector, in the Drug Manufacturers - Specialty & Generic industry. The company reports 82 employees.

Over the past 52 weeks the price has ranged from $1.65 to $3.07. The most recent close on file for AYTU is $2.21, dated September 4, 2026. That is −$0.08 (−3.49%) against the previous close. The latest close sits 33.94% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $66.38M. Against the prior fiscal year total of $65.18M, that is a change of +1.84%. The same year closed with a net loss of $13.56M. Profit margin runs at −60.17%. That is 57 percentage points below the Drug Manufacturers - Specialty & Generic median of −3.14%. Trailing earnings per share are −4.38.

Across the 4 fiscal years on file, revenue moves from $96.67M in 2022 to $66.38M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 0.42 times revenue. On price-to-sales that is 0.2 times the Drug Manufacturers - Specialty & Generic median of 2.3. The medians here are taken across 103 Drug Manufacturers - Specialty & Generic companies that report the metric.

The trailing one-year price return is −2.21%. Measured over 10 years, that is −69.49% a year compounded. Beta against the wider market is reported at 0.27. Daily returns over the trailing 10 years annualize to a volatility of 182.94%.

Growth & Income

The record shows no dividend for AYTU.

2026 is still running; the price is −15.00% year to date. Across the complete calendar years on file, 2025 returned +52.94% and 2018 returned −98.23%. Of the 9 complete calendar years on file, 2 finished higher.

Peer Comparison

Aytu BioPharma, Inc. (AYTU) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Aytu BioPharma, Inc. AYTU $23.72M —
Takeda Pharmaceutical Company Limited TAK $58.92B —
Teva Pharmaceutical Industries Limited TEVA $42.37B 60.6
Haleon plc HLN $42.22B 20.0

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 19.3x. Aytu BioPharma, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$58.92B

 TEVA

Teva Pharmaceutical Industries Limited

$42.37B

 HLN

Haleon plc

$42.22B

 ZTS

Zoetis Inc.

$31.33B

 UTHR

United Therapeutics Corporation

$20.91B

 VTRS

Viatris Inc.

$19.39B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Aytu BioPharma, Inc.

Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.

Visit website →